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Abstract 
Background: Replacing glucose with a better biocompatible osmotic agent in peritoneal dialysis (PD) solutions is 
needed in PD clinic. We previously demonstrated the potential of hyperbranched polyglycerol (HPG) as a replace-
ment for glucose. This study further investigated the long-term effects of chronic exposure to HPG as compared to a 
glucose-based conventional PD solution on peritoneal membrane (PM) structure and function in rats.
Methods: Adult male Wistar rats received once-daily intraperitoneal injection of 10 mL of HPG solution (1 kDa, HPG 
6%) compared to Physioneal™ 40 (PYS, glucose 2.27%) or electrolyte solution (Control) for 3 months. The overall 
health conditions were determined by blood chemistry analysis. The PM function was determined by ultrafiltration, 
and its injury by histological and transcriptome-based pathway analyses.
Results: Here, we showed that there was no difference in the blood chemistry between rats receiving the HPG and 
the Control, while PYS increased serum alkaline phosphatase, globulin and creatinine and decreased serum albumin. 
Unlike PYS, HPG did not significantly attenuate PM function, which was associated with smaller change in both the 
structure and the angiogenesis of the PM and less cells expressing vascular endothelial growth factor, α-smooth 
muscle actin and MAC387 (macrophage marker). The pathway analysis revealed that there were more inflammatory 
signaling pathways functioning in the PM of PYS group than those of HPG or Control, which included the signaling for 
cytokine production in both macrophages and T cells, interleukin (IL)-6, IL-10, Toll-like receptors, triggering receptor 
expressed on myeloid cells 1 and high mobility group box 1.
Conclusions: The results from this experimental study indicate the superiority of HPG to glucose in the preservation 
of the peritoneum function and structure during the long-term PD treatment, suggesting the potential of HPG as a 
novel osmotic agent for PD.
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Background
Peritoneal dialysis (PD) is one of the effective options for 
treating renal failure in patients in nephrology clinics, 
evidenced by the fact that as compared to hemodialysis 
(HD), PD has better or equal clinical outcomes [1–3], 
and is also associated with an increase in quality-of-life 
and therapy-satisfaction scores in patients [4, 5]. Dianeal 
and Physioneal (PYS) from Baxter are the most com-
mon solutions for PD, and contain a high concentration 
of glucose as an osmotic agent. However, increasing evi-
dence in the literature clearly demonstrates that the long-
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is associated with systemic health complications (e.g. 
an increase in cardiovascular disease and the loss of 
residual kidney function) in PD patients particularly for 
those with diabetes [6–10], and causes local deleterious 
effect on the peritoneum—leading to ultrafiltration fail-
ure (UFF) and resulting in poor outcome of PD [11, 12]. 
Thus, there is an unmet need for glucose-free PD solu-
tions in order to improve clinical outcomes of PD.
Hyperbranched polyglycerol (HPG) is a highly hydro-
philic, water-soluble branched polyether polymer, and 
can be prepared by a one-step synthesis via ring-opening 
multi-branching polymerization of glycidol [13]. Recent 
reports in literature demonstrate the biocompatibility 
and potential use of this macromolecule in many dif-
ferent biomedical applications, such as a human serum 
albumin substitute [14], a drug carrier [15, 16] and a 
colloid for cold preservation of cells or organs [17]. Our 
preliminary studies have shown that HPG (0.5–3  kDa)-
based PD solutions can be prepared by varying the HPG 
concentration from 2.5 to 15% (w/v) within an osmolality 
range (294–424 mOsm/kg) and neutral pH (6.6–7.4) that 
are comparable to Dianeal (2.5% glucose, 395  mOsm/L, 
pH 5.2) and PYS (2.27% glucose, 395  mOsm/L, pH 7.4) 
[18, 19], and by a single dwell time these HPG-based PD 
solutions produced similar or significantly better fluid 
and waste removal while causing less damage to perito-
neal membrane (PM) in rats compared to either Dianeal 
(2.5% glucose) or PYS (2.27% glucose) [18, 19]. The objec-
tive of the current study was to investigate the long-term 
effects of HPG-based PD solution (denoted here as HPG) 
compared to conventional glucose-based PYS in rats, 
especially on the PM structure and function.
Methods
Reagents and animals
Physioneal™ 40 solution (denoted as PYS here) was pur-
chased from Baxter Healthcare Co. (Deerfield, IL, USA). 
Primary antibodies were: mouse anti-vascular endothe-
lial growth factor (VEGF) antibody (Cat#: NB100-664, 
Novus Biologicals, Littleton CO, USA), mouse mono-
clonal anti-α-smooth muscle actin (SMA) (clone 1A4, 
Sigma-Aldrich, Oakville, ON, Canada), and mouse 
monoclonal anti-MAC387 antibody (Clone MAC387, 
Santa Cruz Biotech Inc., Dallas, TX, USA), and mouse 
monoclonal anti-β-actin (clone AC-40, Sigma-Aldrich, 
Canada). Secondary horseradish peroxidase (HRP)-con-
jugated anti-mouse IgG HRP (sc-2314) was from Santa 
Cruz Biotech.
Male outbred Wistar rats (~400  g bodyweight, 
12–14 weeks old) were purchased from the Charles River 
Laboratories International, Inc. (Wilmington, MA, USA), 
and maintained in the animal facility of the Jack Bell 
Research Centre at the University of British Columbia 
(UBC) (Vancouver, BC, Canada). Animal experiments 
were performed in accordance with the Canadian Coun-
cil on Animal Care guidelines under protocols approved 
by the animal use subcommittee of UBC.
Synthesis and characterization of HPG
HPG (1  kDa) was synthesized by anionic ring opening 
multi-branching polymerization, and its characteristics 
were verified as described previously [18, 19].
Preparation of HPG‑based and control solutions
HPG solution (denoted as HPG, approximately 402 mOs-
mol/kg, pH 7.4) was prepared by dissolving of HPG 
(1 kDa, 6% w/v) in PD buffer solution similar to PYS solu-
tion containing sodium chloride (NaCl, 538 mg/100 mL), 
sodium lactate (NaC3H5O3, 168  mg/100  mL), calcium 
chloride dehydrate (CaCl2 2H2O, 18.4  mg/100  mL), 
magnesium chloride hexahydrate (MgCl2 6H2O, 
5.1  mg/100  mL) and sodium bicarbonate (NaHCO3, 
210  mg/100  mL). The osmolality and pH of HPG solu-
tion were approximately the same as those of PYS (2.27% 
glucose, 395  mOsm/L, pH 7.4). The electrolye solution 
(denoted as Control, 251 mOsmol/kg, pH 7.4) had the 
same composition as HPG solution except that the HPG 
polymer was omitted. Both HPG and the electrolyte solu-
tions were filter-sterilized prior to use in rats.
Chronic rat model of PD, bodyweight and peritoneal 
equilibrium test (PET)
Chronic rat model of PD—the Wistar rats receiving 
once-daily intraperitoneal instillation of 10  mL of a PD 
solution was established as previously described [20–22]. 
In brief, after anesthesia with isoflurane, 10 mL of a pre-
warmed PD solution (HPG, PYS or Control) were slowly 
injected to the peritoneal cavity at the abdominal mid-
line. Animals awoke within 1–2 min after the procedure, 
and had free access to food and tap water. Animals in 
Sham group were treated in the same manner including 
the needle puncture but without fluid injection.
After 3  months of daily exposure to the PD solutions, 
both bodyweight gain (BWG) and PM ultrafiltration (UF) 
were determined. BWG in each rat was determined as fol-
lows: BWG (%) = (final bodyweight—initial bodyweight)/
initial bodyweight. The PM function was examined using 
UF. In brief, the UF was performed by intraperitoneal 
injection (IP) of 30 mL of PYS. After 4 h of dwelling time, 
the peritoneal fluid was recovered using a syringe, and its 
volume was used for calculating the UF capacity.
Histological analyses
After UF measurement, two strips of parietal perito-
neum from each rat were collected, one from left lumbar 
abdominal region and the other from the right region. The 
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histological analysis of the submesothelial thickness was 
performed in hematoxylin and eosin (H&E) stained tissue 
section as described previously [18]. The number of the 
blood vessel and capillaries per millimeter of the perito-
neum section was counted longitudinally in the PM (both 
submesothelial and muscle-associated connective tissue 
layers) of the whole tissue sections. In addition to H&E 
stain, the tissue sections were also stained with Masson’s 
trichrome method for the examination of collagen fibers.
Immunohistochemical analysis
The expression of VEGF, α-SMA and MAC387 in the 
tissue sections of six rats randomly selected from each 
group was examined using a routine immunohistochemi-
cal method as described by our lab [23].
Tissue preparation and RNA extraction
Four rats were randomly selected from each group except 
of three in Sham. The parietal peritoneum tissues were col-
lected as described in above “Histological Analyses” section, 
and were snap-frozen with liquid nitrogen first, and then 
stored in −80 °C until use. Total RNA was extracted by using 
mirVana™ isolation kit (Ambion, Austin, TX, USA) from the 
PM that was carefully pealed off from the frozen peritoneum 
tissue. The RNA samples with ≥8 of RNA Integrity Number 
(RIN) were selected for microarray analysis.
Microarray and ingenuity pathway analyses (IPA)
Microarray analysis was performed in the Laboratory 
for Advanced Genome Analysis at Vancouver Prostate 
Centre (Vancouver, BC, Canada) following a standard-
ized protocol as described previously [24]. Only the 
genes with p ≤ 0.05 (t test) and ≥ twofold change were 
uploaded into IPA software (Ingenuity Systems, Redwood 
City, CA, USA) to examine gene enrichment pathways.
The signaling pathway search was performed using the 
keywords related to inflammation, such as “B cell devel-
opment”, “complement”, “granulocyte/agranulocyte adhe-
sion and diapedesis”, “antigen presentation pathway”, and 
so on, to identify all the genes related to these cellular 
functions. After that, the genes associated with these 
pathways were separately imported into the “Canoni-
cal Pathway” frame of the IPA software to determine 
whether or not the signaling pathways were significantly 
regulated by each treatment (HPG, PYS or Control) com-
pared to Sham or HPG or PYS compared to Control.
Blood chemistry
A comprehensive metabolic panel of 14 blood substances, 
including alanine aminotransferase (ALT), albumin 
(ALB), alkaline phosphatase (ALP), amylase (AMY) total 
calcium (Ca2+), creatinine (Cre), globulin (Glob), glucose, 
phosphorus (Phos), potassium (K+), sodium (Na+), total 
bilirubin (TBIL), total protein (TP), and urea nitrogen 
(BUN), in heparinized whole blood samples were deter-
mined in blood using the VetScan® Comprehensive Diag-
nostic Profile reagent rotor with the VetScan Chemistry 
Analyzer VS2 (Abaxis, Inc., Union City, CA, USA) in the 
Animal Unit Hematology Diagnostic Laboratory at Jack 
Bell Research Centre (Vancouver, BC, Canada).
Statistical analysis
Data were presented as mean  ±  standard derivation 
(SD) of each group. Both Student’s t test with two-tailed 
distribution and analysis of variance (ANOVA) (Graph-
Pad Prism software, Inc., La Jolla, CA, USA) were used 
as appropriate for data analyses. A p value of ≤0.05 was 
considered significant.
Results
Unlike PYS, HPG solution does not have specific impact 
on overall health status
The overall health status of rats was determined by both 
BWG and changes in a comprehensive metabolic panel 
of 14 blood substances that represent the basic metab-
olism (glucose) and electrolytes (Na+, K+, Ca2+, and 
Phos), and markers of both kidney and liver functions. 
After 3  months of daily treatment with different solu-
tions, there was no significant difference in the BWG in 
Control (46.04 ±  15.88%, n =  7), PYS (39.75 ±  15.66%, 
n = 7) and HPG (35.01 ± 5.95%, n = 8) as compared to 
Sham (50.67 ±  12.42%, n =  3) using one-way ANOVA 
with Dunnett’s multiple comparison test (p = 0.246). The 
blood chemistry test was performed once every month 
during 3  months of the treatment. Overall, the changes 
of the blood substances in response to daily injection of 
HPG solution versus electrolyte Control (without HPG) 
or Sham were not significantly different (Additional 
file 1: Table S1). As compared to the initial levels (prior 
to the treatment), the treatment procedure nonspecifi-
cally (regardless of Sham or injection of any of Control, 
PYS and HPG solutions) induced an increase in Na+, 
TBIL and TP, and a decrease in Phos (Additional file  1: 
Table S1). However, as compared to Control or HPG, 
IP injection of PYS significantly changed the levels of 
Cre, ALP, ALB and Glob (including ALB/Glob ratio) 
during 3  months of treatment (Sham: n  =  3; Control: 
n = 7; PYS: n = 7; HPG: n = 8). As shown in Fig. 1 or 
in Additional file 1: Table S1, unlike HPG, PYS increased 
serum levels of Cre significantly in comparison to the 
Control or HPG (PYS vs. Control: p =  0.0231, HPG vs. 
Control: p = 0.8439, HPG vs. PYS: p = 0.0269, two-way 
ANOVA) (Fig.  1a), ALP (PYS vs. Control: p  =  0.0074, 
HPG vs. Control: p = 0.4325, HPG vs. PYS: p = 0.0204, 
two-way ANOVA) (Fig.  1b) and of Glob (PYS vs. Con-
trol: p = 0.0141, HPG vs. Control: p = 0.7534, HPG vs. 
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PYS: p  =  0.0171, two-way ANOVA) (Fig.  1c). The lev-
els of ALB in PYS but not HPG decreased as compared 
to that in Control (PYS vs. Control: p = 0.003, HPG vs. 
Control: p = 0.7796, HPG vs. PYS: p = 0.0403, two-way 
ANOVA) (Fig. 1d), and more significant differences were 
seen from the calculation of ALB/Glob ratio among these 
groups (PYS vs. Control: p =  0.0022, HPG vs. Control: 
p = 0.5636, HPG vs. PYS: p = 0.0114, two-way ANOVA) 
(Fig. 1e).
Unlike PYS, HPG solution does not specifically attenuate 
PM function
The PM function was determined using UF capac-
ity after 3  months of daily exposure to Control, PYS 
Fig. 1 The chemical changes in the blood of rats after 3 months of intraperitoneal injection of PD solutions. Male Wistar rats received once-daily 
intraperitoneal injection of Control (n = 7), PYS (n = 7) or HPG (n = 8), or needle puncture as Sham Control (n = 3). The blood chemistry test was 
performed three times during 3-month period of treatment (once at the end of each month). a Creatinine (Cre) (PYS vs. Control: p = 0.0231, HPG 
vs. Control: p = 0.8439, HPG vs. PYS: p = 0.0269). b Alkaline phosphate (ALP) (PYS vs. Control: p = 0.0074, HPG vs. Control: p = 0.4325, HPG vs. PYS: 
p = 0.0204). c Globulin (Glob) (PYS vs. Control: p = 0.0141, HPG vs. Control: p = 0.7534, HPG vs. PYS: p = 0.0171). d Albumin (ALB) (PYS vs. Control: 
p = 0.003, HPG vs. Control: p = 0.7796, HPG vs. PYS: p = 0.0403). e ALB/Glob ratio (PYS vs. Control: p = 0.0022, HPG vs. Control: p = 0.5636, HPG vs. 
PYS: p = 0.0114). Data were presented as mean ± standard derivation (SD) of each group, and were statistically analyzed using two-way ANOVA
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or HPG solution. As shown in Fig.  2, there was no sig-
nificant difference in the UF of the PM between Sham 
(26.33 ± 3.51 mL, n = 3) and Control (26.17 ± 3.06 mL, 
n  =  7). Statistical analysis using two-tailed t test indi-
cated that as compared to Control group, no signifi-
cant difference from HPG group was found in this 
limited number of animals (17.64  ±  9.34  mL, n  =  8) 
(p  =  0.0568), while the rats in PYS group lost the PM 
function (8.64 ± 5.14 mL, n = 7) as compared with Con-
trol (p < 0.0001) or HPG (p = 0.0453). After 4 h of dwell 
time only a few milliliters of dialysate were recovered in 
some rats, and were heavily “contaminated” with tissue 
debris and the blood, so that we were not able to deter-
mine the PM function using other parameters, such as 
the removal of the urea, creatinine, or sodium in these 
samples.
Unlike PYS, HPG solution does not significantly induce 
morphological and structural changes of PM
To investigate the pathological changes in the PM 
after daily exposure to different solutions (particularly 
PYS and HPG), histology analysis of the PM was per-
formed after UF determination. In H&E stained sec-
tions (Fig.  3a, top panel), the number of small blood 
vessels and capillaries in the deeper loose adipose 
connective tissues, and the thickness of the submeso-
thelial compact zones were examined. As showed in 
Fig. 3b, rats in PYS group had the thickest submesothe-
lial compact zones (98.25 ±  32.73  µm, n =  14 sections 
of seven rats), which were significantly larger than those 
in Control group (53.57 ±  20.2  µm, n =  14 sections of 
seven rats) (p  =  0.0007, two-tailed t test) or in HPG 
group (66.68 ± 21.11 µm, n = 16 sections of eight rats) 
(p = 0.0016, two-tailed t test). Also, there was no statisti-
cal difference in the thickness of the submesothelial layer 
between the Control and HPG groups (p = 0.1184, two-
tailed t test). Similar to the changes in the submesothelial 
layer thickness in these groups, more blood vessels and 
capillaries in PYS group (3.17  ±  1.18 per mm, n  =  14 
sections of seven rats) were seen than those of Control 
group (1.47 ± 0.75 per mm, n = 14 sections of seven rats) 
(p < 0.0001, two-tailed t test) or HPG group (2.36 ± 1.32 
per mm, n  =  16 sections of eight rats) (p  =  0.0454) 
(Fig.  3c). Furthermore, the trichrome stain indicated 
the deposition of collagen (blue color) within the PM. 
As shown in Fig. 3a (bottom panel), there was clearly an 
increase in collagen accumulation in all of 3 groups (Con-
trol, PYS and HPG) as compared to that in Sham, but it 
was difficult to quantitatively compare the differences in 
the collagen accumulation between Control and PYS or 
HPG because the integrity of collagen deposition might 
be affected by the test of UF.
Compared to PYS, HPG solution induces less VEGF 
expression, macrophage activation and α‑SMA‑expressing 
cell differentiation
To further understand the pathways by which PYS 
induced severe pathological changes in the peritoneum 
compared to HPG, the expression of α-SMA (a marker 
of myofibroblast differentiation), MAC387 (a marker of 
macrophages) and VEGF (a pro-angiogenic growth fac-
tor) was examined using immunohistochemical stain 
of peritoneal tissue sections. As shown in Fig.  4a, there 
were more cells stained positively with α-SMA in tis-
sue sections of PYS group than those in HPG or Control 
group (15.0  ±  6.95 in PYS versus 2.71  ±  1.87 in HPG, 
p =  0.0019, two-tailed t test, n =  6). In addition to the 
positive stain of α-SMA in smooth muscle cells of the 
blood vessels, myofibroblasts were seen in the submeso-
thelial layer as well as on the surface of the peritoneum 
in PYS group, whereas in other groups fewer of these 
cells were observed on the peritoneal surface. Also, there 
were more infiltrating macrophages in PYS than in HPG 
group (20.83 ± 14.03 in PYS versus 7.58 ± 3.75 in HPG, 
p = 0.0494, two-tailed t test, n = 6), which is consistent 
with more severity of peritoneal injury in PYS than that 
in HPG. In addition to that, the macrophages in the PYS 
group were localized in both inside the submesothelial 
layer and on its surface (Fig. 4b).
To further confirm the increase of the neoan-
giogenesis in the PM after chronic exposure to PYS 
compared to HPG, the expression of VEGF, a neoan-
giogenesis factor, in PM sections was examined using 
Fig. 2 HPG has better preservation of peritoneal membrane func-
tion. The ultrafiltration as a parameter of peritoneal function was 
measured after 3 months of daily exposure of peritoneal cavity to 
the PD solutions. Each rat received intraperitoneal injection of 30 mL 
of PYS. After 4 h of dwell time, the fluid was recovered from the 
peritoneal cavity using a syringe, and its volume was measured. Data 
were presented as mean ± SD of each group (Sham: n = 3; Control: 
n = 7; PYS: n = 7; HPG: n = 8), and were statistically analyzed using 
two-tailed t test
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immunohistochemical staining. As shown in Fig.  4c, 
there were more VEGF-expressing cells in the submeso-
thelial membranes in PYS group than that of HPG or 
Control group (58.83 ± 31.34 in PYS versus 22.8 ± 10.88 
in HPG, p  =  0.0307; 58.83  ±  31.34 in PYS versus 
3.33  ±  0.88 in Control, p  =  0.0019; two-tailed t test, 
n  =  6 rats), which was in parallel with the most blood 
vessels found in the PYS group (Fig. 3c).
Fig. 3 HPG has better protection of peritoneal membrane structure. At the end of 3-month treatment, peritoneal tissue sections (2 sections/rat) 
were taken from rats (Sham: n = 3; Control: n = 7; PYS: n = 7; HPG: n = 8) after 4 h of PYS exposure for UF test. a A typical microscopic image of 
the peritoneal tissue sections in each group, and were stained using either H&E (top panel) or Masson’s trichrome method (bottom panel). H&E stain 
showing the thickness of the peritoneal membrane indicated by the distance between two arrows. Nuclear dark blue stain cellular infiltrates; blue 
arrows blood vessels; black thin bar 100 µm. Masson’s trichrome stain showing collagen deposition (dark blue). b The thickness of submesothelial 
layer in each tissue section was measured using the Digital Image Hub software. Data were presented as mean ± SD of each group, and were 
statistically analyzed using two-tailed t test. c Angiogenesis in the peritoneal membrane was represented by the number of the blood vessels and 
capillaries per millimeter. Data were presented as mean ± SD of each group, and were statistically analyzed using two-tailed t test
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Fig. 5 Changes in transcriptome in the PM of rats receiving daily i.p. injection of electrolyte Control, PYS or HPG solution. Venn diagram analysis 
of microarray data (four separate samples in each group, n = 4; one rat in Sham provided two samples) of Control, PYS or HPG was performed as 
compared to those of Sham or of PYS or HPG as compared to Control using the Agilent Gene Spring software. Only the transcripts that were signifi-
cantly changed (p ≤ 0.05; FC ≥ 2.0) as compared to Sham or Control group were included and presented in this analysis. Top panel The changes of 
gene expression in Control, PYS or HPG using Sham as a reference. Bottom panel The change of gene expression in PYS or HPG using Control as a 
reference. Positive FC up-regulated, negative FC down-regulated
(See figure on previous page.)  
Fig. 4 HPG induces less VEGF production, less myofibroblast differentiation and lower macrophage activation. The expression of VEGF, α-SMA and 
MAC387 in the peritoneal tissue sections was examined using a routine immunohistochemical method. Data were a typical microscopic view of 
the peritoneal tissue sections in each group. a VEGF was detected using mouse monoclonal anti-VEGF antibody from Novus. Left graph a typical 
microscopic view, Dark brown stain VEGF-expressing cells (pointed by red arrows), Bv blood vessels, M muscle, black small bar 10 µm. Right graph 
VEGF-expressing cells per 200 μm PM length in cross sections. Data were presented as mean ± SD (n = 6) and were analyzed using t test. b α-SMA 
(a myofibroblast marker) was detected using mouse monoclonal anti-α-SMA antibody from Sigma-Aldrich. Left graph a typical microscopic view, 
Dark brown stain α-SMA-expressing cells or myofibroblasts (pointed by red arrows), Bv blood vessels, M muscle, black small bar 10 µm. Right graph 
α-SMA-expressing cells per 200 μm PM length in cross sections. Data were presented as mean ± SD (n = 6) and were analyzed using t test. c 
Macrophages were detected using mouse monoclonal anti-MAC387 antibody from Santa Cruz Biotech. Left graph a typical microscopic view, Dark 
brown stain MAC387-expressing cells or macrophages (pointed by red arrows), M muscle, black small bar 10 µm. Right graph MAC387-expressing 
cells per 200 μm PM length in cross sections. Data were presented as mean ± SD (n = 6) and were analyzed using t test
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Compared to PYS, HPG solution significantly induces less 
inflammatory signaling pathways and exclusively activated 
lipid metabolism‑related pathway
To further understand the molecular signaling path-
ways mediating the effects of daily injection of electro-
lyte Control, PYS or HPG solution on PM structure and 
function, the transcriptome-based pathway analysis was 
performed. Compared to Sham as a baseline there were 
more gene alterations in HPG group (785 up-regulated, 
857 downregulated) than those in both PYS group (606 
up-regulated, 507 downregulated) and Control (529 up-
regulated, 439 down-regulated) (Fig.  5, upper panel). 
Also when HPG or PYS was compared with Control, 
a similar trend (HPG  >  PYS) was noted but with less 
affected gene expression (Fig. 5, bottom panel). Pathway 
analysis of these gene expression profilings showed that 
in comparison with Control, PYS or HPG with Sham, 
more pathways related to inflammation were signifi-
cantly induced (p < 0.05) in the PM of rats receiving PYS 
than those in HPG or Control (Table 1), which included 
“Role of hypercytokinemia/hyperchemokineemia in 
the pathogenesis”, “IL-6 signaling”, “Toll-like signal-
ing”, “HMGB1 signaling”, and so on. Also the p values 
of the pathways activated in all of three groups, such as 
“Granulocyte or agranulocyte adhesion and diapedesis” 
and “Acute phase response signaling” reached a higher 
statistical significance in PYS group than those in HPG 
or Control group (Table 1). The higher activation of the 
inflammatory pathways in PYS group was consistent 
with a significant up-regulation of several well-known 
pro-inflammatory mediators, such as TNF, IL-1β, CCL2 
and MMP9, which were not seen in either HPG or Con-
trol group (Tables  2, 3, 4). When we compared PYS or 
HPG with Control, there were still more inflammatory 
pathways being significantly affected by glucose-based 
PYS than those seen in HPG group (nine in PYS ver-
sus five in HPG) (Table 5), which included “Acute phase 
response signaling”, “Inhibition of matrix metallopro-
teinase” and IL-6 signaling”. Similarly, the highly up-
regulated TNF and MMP9 were found in PYS but not 
in HPG when Control was used as a reference in analy-
sis (Tables 6, 7). All these data implied that TNF and/or 
MMP9-dependent pathways were specifically activated 
in the PM by chronic exposure to PYS.
In addition to the pathways mediating inflammation as 
listed in Table 1, the analysis of global canonical pathways 
Table 1 The p values (as a function) of  affected inflammatory signaling pathways between  Control, PYS and  HPG com-
pared to Sham
The p value was calculated by t test as compared with the baseline sham control
DC dendritic cell, NK natural killer, Th T helper, MΦ macrophage, ICOS inducible costimulator, ICOSL inducible costimulatory ligand, TREM1 triggering receptor 
expressed on myeloid cells 1, MIF macrophage migration inhibitory factor, HMGB1 high mobility group box 1, NS not significant, + up-regulated number of genes, 
− down-regulated number of genes
Signaling pathways (total number of genes) Control PYS HPG
B cell development (22) 6.3 × 10−6 (+7) 0.001 (+5) 0.0002 (+6)
Complement (34) 1 × 10−6 (+8, −1) 1 × 10−5 (+8) 0.001 (+7)
Cross talk between DCs and NK cells (68) 0.001 (+4, −6) 0.0025 (+4, −4) 0.0016 (+5, −6)
Granulocyte adhesion and diapedesis (145) 0.0001 (+6, −7) 1 × 10−11 (+18, −8) 0.0032 (+8, −5)
Agranulocyte adhesion and diapedesis (154) 0.0001 (+8, −7) 1 × 10−10 (+18, +7) 0.004 (+10, −4)
ICOS/ICOSL signaling in Th cells (96) 1.3 × 10−5 (+9, −4) 0.0032 (+6, −3) 0.01 (+8, −2)
Antigen presentation pathway (22) 0.001 (+4) 0.0032 (+4) 0.01 (+4)
Nur 77 signaling in T cells (43) 5 × 10−5 (+6, −2) NS (+2, −2) 0.0316 (+4, −1)
Acute phase response signaling (157) 0.001 (+8, −4) 1 × 10−6 (+17, −3) 0.0316 (+9, −3)
CD28 signaling in Th cells (106) 1 × 10−5 (+10, −4) 0.0126 (+7, −2) 0.0316 (+7, −2)
IL-17 signaling in fibroblast (23) NS (−2) 0.0501 (+3, −1) 0.0315 (+1, −3)
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (27) 0.00316 (+2, −1) 3.2 × 10−8 (+7, −2) NS (−2)
IL-10 signaling (65) NS (+2, −3) 1 × 10−5 (+8, −3) NS (+1, −3)
Differential regulation of cytokine production in MΦ and Th cell (15) NS (+1, −1) 0.0001 (+5) NS (−1)
Inhibition of matrix metalloproteinase (36) NS (+1, −1) 0.002 (+4) NS (+4)
TREM1 signaling (67) NS (+4, −1) 0.0025 (+7, −1) NS (+2, −1)
IL-6 signaling (114) NS (+1, −5) 0.01 (+7, −3) NS (+1, −4)
Toll-like receptor signaling (71) NS (+1, −1) 0.0126 (+6, −1) NS (−2)
MIF-mediated glucocortical regulation (29) NS (+1) 0.0501 (+4) NS (+3)
MIF regulation of innate immunity (73) NS (+1) 0.0501 (+4) NS (+3, −1)
HMGB1 signaling (112) NS (+1, −5) 0.0501 (+6, −2) NS (+1, −3)
Page 10 of 17Du et al. J Transl Med  (2016) 14:338 
showed the function of “Triacylglycerol degradation”, 
CDP diacylglycerol biosynthesis I”, “Phosphotidylglyc-
erol biosynthesis II (non plastidic)” and “Triacyglycerol 
biosynthesis” was found only in the MP of rats receiving 
HPG (Table 8), which may be related to the local metabo-
lism of this polymer.
Discussion
Our previous studies have demonstrated the efficacy of 
small HPG molecules (0.5–3  kDa) as potential osmotic 
agents in fluid removal and their biocompatibility with 
the peritoneum in a rat model of acute (4 h) PD [18, 19]. 
The present study has compared the long-term effects of 
HPG (1  kDa) with glucose on overall health status and 
its local influence on the peritoneum using a rat model 
of chronic PD, and has demonstrated that as compared 
to electrolyte solution, HPG did not induce any change 
in the blood chemistry, but IP injection of PYS signifi-
cantly changed the levels of Cre, ALP, ALB and Glob 
(including ALB/Glob ratio) during 3  months of treat-
ment. These data suggest that the long-term effects of 
HPG on the glucose metabolism, electrolytes, liver and 
kidney function were not different from those of Control, 
whereas the use of PYS may associate with the dysfunc-
tion of the kidney and/or chronic immune activation or 
inflammation as PYS-treated rats have the elevated levels 
Table 2 The inflammatory signaling pathways and related gene transcripts affected by daily injection of electrolyte solu-
tion (Control) compared to Sham
The affected signaling pathways were ranked from the most (top) to the least significant (bottom) based on the p value
DC dendritic cell, NK natural killer, Th T helper, MΦ macrophage, ICOS inducible costimulator, ICOSL inducible costimulatory ligand, TREM1 triggering receptor 
expressed on myeloid cells 1, MIF macrophage migration inhibitory factor, HMGB1 high mobility group box 1, NS not significant
Signaling pathways (p value) Up regulated genes Down regulated genes
Complement (1 × 10−6) C2, C3, C6, C4BPA, CFD, ITGB2, ITGAM, ITGAX C7
B cell development (6 × 10−6) HLA-DRA, HLA-DRB5, HLA-DQB1, IL7, IL7R, PTPRC, 
SPN
–
CD28 signaling in Th cells (1 × 10−5) HLA-DRA, HLA-DRB5, HLA-DQB1, CD247, CD3E, 
CD3G, GRAP2, PAK1, PTPRC, VAV1
Calm1, FOS, PIK3C2G, PIK3R3
ICOs/ICOSL signaling in Th cells (1.3 × 10−5) CD247, CD3E, CD3G, GRAP2, HLA-DQB1, HLA-DRA, 
HLA-DRB5, PTPRC, VAV1
Calm1, CAMK2D, PIK3C2G, PIK3R3
Nur 77 signaling in T cells (5 × 10−5) CD247, CD3G, HLA-DRA, HLA-DRB5, HLA-DQB1, 
CD3E
Calm1, CASP3
Agranulocyte adhesion and diapedesis (0.0001) ACTC1, AOC3, CCL4, CCL9, EZR, IL18, ITGB2, MYH3 CCL20, CD34, CLDN5, CXCL2, CXCR4, ICAM2, 
MMP27
Granulocyte adhesion and diapedesis (0.00013) CCL4, CCL9, EZR, IL18, ITGAM, ITGB2 CCL20, CLDN5, CXCL2, CXCR4, ICAM2, IL1R2, 
MMP27
Cross talk between DCs and NK cells (0.001) ACTG2, HLA-DRA, HLA-DRB5, IL18 IL6, MIBC, FSCN1, CAMK2D, ACTC1, TNFSF10
Antigen presentation pathway (0.001) CIITA, CD74, HLA-DRA, HLA-DRB5 –
Acute phase response signaling (0.001) AGT, C2, C3, C4BPA, IL18, KLKB1, RBP4, SERPINA3 FOS, IL6, PIK3R3, VWF
Role of hypercytokinemia/hyperchemokinemia in 
the pathogenesis (0.003162)
CCL4, IL18 IL6
TREM1 signaling (0.0631, NS) CIITA, IL18, ITGAX, TLR11 IL6
IL-10 signaling (0.0631, NS) IL18, IL10RA FOS, IL6, IL1R2
Differential regulation of cytokine production in 
MΦ and Th cell (0.1, NS)
CCL4 IL6
IL-6 signaling (0.1259, NS) IL18 IL6, FOS, IL1R2, PIK3C2G, PIK3R3
HMGB1 signaling (0.1259, NS) IL18 IL6, FOS, PIK3C2G, PIK3R3, RHOJ
Inhibition of matrix metalloproteinase (0.2512, NS) THBS2 MMP27
IL-17 signaling in fibroblast (0.2512, NS) IL6, FOS
MIF regulation of innate immunity (0.3162, NS) CD74 FOS
MIF-mediated glucocortical regulation (0.5012, NS) CD74 –
Toll-like receptor signaling (1.0, NS) IL18 FOS
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of serum Cre, ALP and Glob and a decrease in ALB or 
ALB to Glob ratio. Interestingly, hypoalbuminemia is of 
concern in the disease management of PD patients [25], 
suggesting that the use of HPG-based PD solution may 
improve this condition. Locally, although there were 
some tissue damage and functional impairment in the 
PM in rats after 3 months of daily exposure to hyperos-
motic HPG solution compared to hypoosmotic electro-
lyte solution, the difference between these two groups 
was not significant with this limited number of animals. 
Unlike HPG solution, PYS induced a significant change 
in the structure of PM and attenuates its UF capacity, 
which is associated with increases in angiogenesis or 
VEGF expression, myofibroblast population, macrophage 
infiltration and activation of inflammatory pathways, 
especially the TNF and/or MMP9-dependent pathways 
as indicated by the transcriptome-based analysis.
In PD, glucose has been used as the most common 
osmotic agent for several decades to achieve adequate 
fluid removal. Because of a high level of glucose, and 
Table 3 The inflammatory signaling pathways and  related gene transcripts affected by  daily injection of  PYS solution 
compared to Sham
The affected signaling pathways were ranked from the most (top) to the least significant (bottom) based on the p value
DC dendritic cell, NK natural killer, Th T helper, MΦ macrophage, ICOS inducible costimulator, ICOSL inducible costimulatory ligand, TREM1 triggering receptor 
expressed on myeloid cells 1, MIF macrophage migration inhibitory factor, HMGB1 high mobility group box 1, NS not significant
Signaling pathways (p value) Up regulated genes Down regulated genes
Granulocyte adhesion and diapedesis 
(1 × 10−11)
C5AR1, CCL2, CCL4, CCL19, CCL21, CXCL13, 
CXCL14, CXCR2, EZR, IL1B, IL1RN, ITGB2, MMP9, 
MMP16, SELL, TNF, TNFRSF11B, VCAM1
CLDN5, CXCL2, CXCR4, ICAM2, IL33, IL1RAPL1, 
MMP27, THY1
Agranulocyte adhesion and diapedesis 
(1 × 10−10)
AOC3, C5AR1, CCL2, CCL4, CCL19, CCL21, 
CXCL13, CXCL14, CXCR2, EZR, IL1B, IL1RN, 
ITGB2, MMP9, MMP16, SELL, TNF, VCAM1
CD34, CLDN5, CXCL2, CXCR4, ICAM2, IL33, MMP27
Role of hypercytokinemia/hyperchemokinemia 
in the pathogenesis (3 × 10−8)
CCL2, CCL4, CCR1, CCR5, IL1B, IL1RN, TNF IL6, IL33
Acute phase response signaling (1 × 10−6) A2M, AGT, C3, C4BPA, CFB, FGG, HP, IKBKE, IL1B, 
KLKB1, RBP1, RBP4, SERPINA3, SERPINE1, TNF, 
TNFRSF11B
IL6, IL33, RB97
Complement (1 × 10−5) C3, C6, C4BPA, C5AR1, CFD, ITGB2, CFB, ITGAM –
IL-10 signaling (1 × 10−5) IKBKE, CCR1, CCR5, CD14, FCGR2B, IL1B, IL1RN, 
TNF
IL6, IL33, IL1RAPL1
Differential regulation of cytokine production in 
MΦ and Th cell (0.0001)
CCL2, CCL4, IL1B, LCN2, TNF –
B cell development (0.001) HLA-DRA, HLA-DRB5, IL7, IL7R, PTPRC –
Inhibition of matrix metalloproteinase (0.002) A2M, MMP9, MMP16, TIMP1 MMP27, TIMP4
Cross talk between DCs and NK cells (0.0025) HLA-DRA, HLA-DRB5, TNF, TLR3 IL6, IL4, FSCN1, CAMK2D
TREM1 signaling (0.0025) CCL2, CIITA, FCGR2B, IL1B, NLRP3, TLR3, TNF IL6
ICOS/ICOSL signaling in Th cells (0.00316) HLA-DRA, HLA-DRB5, IKBKE, ITK, PTPRC, GRAPB2 Calm1, CAMK2D, LAT
Antigen presentation pathway (0.00316) HLA-DRA, HLA-DRB5, CD74, CIITA –
IL-6 signaling (0.01) IKBKE, A2M, CD14, IL1B, IL1RN, TNF, TNFRSF11B IL6, IL33, IL1RAPL1
CD28 signaling in Th cells (0.0126) HLA-DRA, HLA-DRB5, PTPRC, PAK1, GRAP2, IKBKE, 
ITK
Calm1, LAT
Toll-like receptor signaling (0.0126) CD14, IL1B, IL1RN, TLR3, TNF, UBD IL33
IL-17 signaling in fibroblast (0.0501) IKBKE, CCL2, LCN2 IL6
MIF-mediated glucocortical regulation (0.0501) CD74, PLA2G2A, PLA2G5, CD14 –
MIF regulation of innate immunity (0.0501) CD74, PLA2G2A, PLA2G5, CD14 –
HMGB1 signaling (0.0501) VCAM1, TNFRSF11B, TNF, SERPINE1, IL1B, CCL2 IL6, IL4
Nur 77 signaling in T cells (0.0631, NS) HLA-DRA, HLA-DRB5 Calm1, CASP3
Page 12 of 17Du et al. J Transl Med  (2016) 14:338 
mostly glucose degradation products in the PD solution 
(e.g. PYS) that can lead to peritoneal membrane dam-
age, fibrosis development and eventually ultrafiltration 
failure [7, 11, 12], alternative osmotic agents, such as 
polyglucose (icodextrin, Baxter Extraneal) or amino acids 
(Baxter Nutrineal) are developed, and their efficiency in 
preserving the peritoneal membrane integrity and func-
tion has been documented in both experimental and clin-
ical studies [20, 26]. However, both icodextrin and amino 
acid therapies have several drawbacks that could limit 
their broad therapeutic uptake. For example, amino acid 
PD therapy has been used in clinical trials to replace only 
one glucose-based PD bag per day; in the mainstream 
clinic, it is typically reserved for PD patients with signifi-
cant cachexia/hypoalbuminemia. Also, amino acids are 
small molecules and therefore are weak osmotic agents, 
and they do cause issues with metabolic acidosis and 
increase nitrogen loading. Icodextrin is a well-established 
glucose polymer only used for the long dwell in a por-
tion of PD patients mostly in developed countries, and 
it is currently not approved for twice daily use and has 
slow fluid kinetics which limits its utility in short dwell or 
CAPD exchange. All these drawbacks in the use of these 
alternative osmotic agents may require us to develop a 
new osmotic agent.
Chronic injury of the PM in response to glucose-based 
PD solution triggers a cascade of chronic inflammation, 
tissue repair and remodeling (e.g. tissue fibrosis, angio-
genesis) [27, 28], which are associated with the pres-
ence of persistent cellular infiltration (e.g. macrophages 
Table 4 The inflammatory signaling pathways and  related gene transcripts affected by  daily injection of  HPG solution 
compared to Sham
The affected signaling pathways were ranked from the most (top) to the least significant (bottom) based on the p value
DC dendritic cell, NK natural killer, Th T helper, MΦ macrophage, ICOS inducible costimulator, ICOSL inducible costimulatory ligand, TREM1 triggering receptor 
expressed on myeloid cells 1, MIF macrophage migration inhibitory factor, HMGB1 high mobility group box 1, NS not significant
Signaling pathways (p value) Up regulated genes Down regulated genes
B cell development (0.00016) HLA-DRA, HLA-DRB5, IL7, IL7R, PTPRC, SPN –
Complement (0.001) C2, C3, C6, C4BPA, C5AR1, CFD, ITGB2 –
Cross talk between DCs and NK cells (0.0016) ACTG2, HLA-DRA, HLA-DRB5, CD83 IL6, MIBC, FSCN1, FSCN2, CAMK2D, ACTG2
Granulocyte adhesion and diapedesis (0.0032) C5AR1, CCL21, CXCL14, EZR, ITGA2, ITGB2, MMP11, 
VCAM1
CCL2, CXCL2, CXCL10, CXCR4, THY1
Agranulocyte adhesion and diapedesis (0.004) ACTG2, VCAM1, EZR, ITGB2, C5AR1, ITGA2, MMP11, 
CXCL14, CCL21, AOC3
CCL2, CXCL2, CXCL10, CXCR4
ICOS/ICOSL signaling in Th cells (0.01) CD247, CD3G, HLA-DRA, HLA-DRB5, ICOSLG, IKBKE, 
ITK, PTPRC
Calm1, CAMK2D
Antigen presentation pathway (0.01) CIITA, CD74, HLA-DRA, HLA-DRB5
Nur 77 signaling in T cells (0.0316) CD247, CD3G, HLA-DRA, HLA-DRB5 Calm1
Acute phase response signaling (0.0316) C2, SERPINA3, IKBKE, ITIH4, C3, FGG, AGT, RBP4, 
C4BPA
IL6, FOS, MAPK11
CD28 signaling in Th cells (0.0316) HLA-DRA, HLA-DRB5, PTPRC, CD247, CD3G, IKBKE, 
ITK
Calm1, FOS
IL-17 signaling in fibroblast (0.0316) IKBKE IL6, FOS, MAPK11
Role of hypercytokinemia/hyperchemokinemia in 
the pathogenesis (0.3162, NS)
– CCCL10, IL6
IL-10 signaling (0.2512, NS) IKBKE IL6, FOS, MAPK11
Differential regulation of cytokine production in MΦ 
and Th cells (0.5012, NS)
– IL6
Inhibition of matrix metalloproteinase (0.0631, NS) LRP1, MMP11, SDC1, THBS2 –
TREM1 signaling (0.5012, NS) CD83, CIITA IL6
IL-6 signaling (0.5012, NS) IKBKE IL6, FOS, MAPK11, CSNK2A2
Toll-like receptor signaling (1.0, NS) – FOS, MAPK11
MIF-mediated glucocortical regulation (0.1259, NS) CD74, PLA2G2A, PLA2G5 –
MIF regulation of innate immunity (0.0794, NS) CD74, PLA2G2A, PLA2G5 FOS
HMGB1 signaling (1.0, NS) VCAM1 IL6, FOS, MAPK11
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and lymphocytes), inflammatory and anti-inflammatory 
factors (e.g. TNF-α, IL-6, TGF-β) and tissue growth fac-
tors (e.g. VEGF, TGF-β) [11, 28–32]. In the comparison 
of HPG with PYS group, our data showed that in PYS 
group there was more damage in the structure of the PM 
as represented as PM thickness; this was positively cor-
related with an increase in infiltrating macrophages and 
more myofibroblasts, which may suggest that an increase 
in infiltrating macrophages is a part of chronic inflamma-
tion cascade activated by PYS, and the mesothelial cells 
in the inflammatory peritoneum may be more prone to 
differentiate to the myofibroblasts. Moreover, VEGF is a 
key factor for the neoangiogenesis, and can be produced 
by many types of cells including peritoneal mesothelial 
cells in response to pro-inflammatory cytokine stimu-
lation [33] or a high-glucose PD solution [34]. We did 
observe an increased expression of VEGF with immu-
nohistochemistry that correlates with an increase in 
neoangiogenesis (capillary density) within the PM in the 
PYS group; this was associated with increased loss of UF 
capacity (Fig. 2). In both experimental and clinical stud-
ies, PM fibrosis and neoangiogenesis are the two most 
important factors closely associated with UFF [35].
Furthermore, our transcriptome-based analysis con-
firmed that many inflammatory pathways were activated 
in the PM of rats receiving daily i.p. injection of either 
HPG or PYS. However, the number of inflammatory path-
ways and degree of statistical significance was greater in 
the PYS than HPG group compared to Sham (Table 1) or 
to Control (Table 5). These findings provide strong bio-
logical connection between the gene expression profiles 
of the PM after exposure to a variety of PD solutions and 
the morphological and functional alterations observed 
in our experiments. Furthermore, one interesting find-
ing from this microarray analysis was the upregulation 
within the PM of triacylglycerol metabolism-related 
Table 5 The p values (as a function) of  affected inflammatory signaling pathways between  PYS and  HPG compared 
to Control
The p value was calculated by t test as compared with the electrolye solution control
DC dendritic cell, NK natural killer, Th T helper, MΦ macrophage, ICOS inducible costimulator, ICOSL inducible costimulatory ligand, TREM1 triggering receptor 
expressed on myeloid cells 1, MIF macrophage migration inhibitory factor, HMGB1 high mobility group box 1, NS not significant, NC no change, + up-regulated 
number of genes, − down-regulated number of genes
Signaling pathways (total number of genes) PYS HPG
B cell development (35) NS (−2) 0.023 (−3)
Complement (37) NS (+2) NS (+1)
Cross talk between DCs and NK cells (89) 0.0083 (+1, −4) NS (−4)
Granulocyte adhesion and diapedesis (177) 1.32 × 10−6 (+11, −2) 0.0014 (+7, −3)
Agranulocyte adhesion and diapedesis (189) 7.4 × 10−5 (+10, −1) 0.0071 (+7, −2)
ICOS/ICOSL signaling in Th cells (122) NS (+2, −2) 0.0063 (+3, −4)
Antigen presentation pathway (37) NS (−2) NS (−1)
Nur 77 signaling in T cells (59) NS (+1, −1) NS (−1)
Acute phase response signaling (169) 7.8 × 10−7 (+11, −2) NS (+4)
CD28 signaling in Th cells (131) NS (+2, −2) 0.0302 (+2, −4)
IL-17A signaling in fibroblast (35) 0.0126 (+1, −2) NS (−1)
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (43) NS (+1) NS (−1)
IL-10 signaling (68) NS (+2, −1) NC
Differential regulation of cytokine production in MΦ and Th cell (18) NS (+1) NC
Inhibition of matrix metalloproteinase (39) 0.0002 (+3, −2) NC
TREM1 signaling (75) NS (+1, −1) NC
IL-6 signaling (127) 0.0021 (+6, −1) NS (+3, −1)
Toll-like receptor signaling (74) NS (+1, −1) NC
MIF-mediated glucocortical regulation (33) NS (+1, −1) NS (+2)
MIF regulation of innate immunity (41) 0.0195 (+2, −1) NS (+2)
HMGB1 signaling (133) 0.0389 (+4, −1) NS (+3)
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pathways with HPG exposure (Table  8), indicating that 
HPG can be probably degraded in part locally by meso-
thelial cells and macrophages in the peritoneal mem-
brane, which however remains further elusive.
One has to acknowledge that there are several limi-
tations of this study in term of scale and clinical rel-
evance. Firstly, this was a small scale of experimental 
study, which was designed to examine the long-term 
impact of HPG on PM structure and function, but not 
on other organs or systems, such as the kidney, liver and 
circulatory system. Secondly, because of the species dif-
ferences (rats versus humans) in the genomes, body size 
and anatomy, organ/tissue structure and function and 
metabolism or physiology, the human reactions to HPG 
versus PYS, particularly the activation of pathways, may 
not be the same as we saw in the rats in this study. Fur-
ther studies using human subjects will be needed to ver-
ify these data. Finally, a deficiency of methodologies for 
Table 6 The inflammatory signaling pathways and related gene transcripts affected by daily injection of PYS compared 
to Control
The affected signaling pathways were ranked from the most (top) to the least significant (bottom) based on the p value
DC dendritic cell, NK natural killer, Th T helper, MΦ macrophage, ICOS inducible costimulator, ICOSL inducible costimulatory ligand, TREM1 triggering receptor 
expressed on myeloid cells 1, MIF macrophage migration inhibitory factor, HMGB1 high mobility group box 1, NS not significant
Signaling pathways (p value) Up regulated genes Down regulated genes
Granulocyte adhesion and diapedesis (1.32 × 10−6) SELL, VCAM1, CXCL13, CXCR2, CXCL14, CCL21, CXCL3, TNF, 
MMP9, CCL19, TNFRSF11B
MMP27, THY1
Agranulocyte adhesion and diapedesis (7.4 × 10−5) SELL, VCAM1, CXCL13, CXCR2, CXCL14, CCL21, CXCL3, TNF, 
MMP9, CCL19
MMP27
Role of hypercytokinemia/hyperchemokinemia in the 
pathogenesis (0.4539, NS)
TNF –
Acute phase response signaling (7.8 × 10−7) SOCS3, HP, C3, ORM1, Saa3, CFB, TNF, A2M, RBP1, FGG, 
TNFRSF11B
NFKBIA, CRABP1
Complement (0.0933, NS) C3, CFB –
IL-10 signaling (0.0692, NS) SOCS3, TNF NFKBIA
Differential regulation of cytokine production in MΦ and Th 
cell (0.2239, NS)
TNF –
B cell development (0.0851, NS) – SPN, HLA-DRA
Inhibition of matrix metalloproteinase (0.0002) TIMP1, A2M, MMP9 MMP27, ADAM12,
Cross talk between DCs and NK cells (0.0083) TNF HLA-DRA, CD226, HLA-E, IL4
TREM1 signaling (0.2818, NS) TNF Tlr11
ICOs/ICOSL signaling in Th cells (0.0912, NS) CAMK4, PIK3C2G NFKBIA, HLA-DRA
Antigen presentation pathway (0.0933, NS) – HLA-DRA, HLA-E
IL-6 signaling (0.0021) SOCS3, CSNK2A1, PIK3C2G, A2M, TNF, TNFRSF11B NFKBIA
CD28 signaling in Th cells (0.1117, NS) CAMK4, PIK3C2G NFKBIA, HLA-DRA
Toll-like receptor signaling (0.2767, NS) TNF NFKBIA
IL-17 signaling in fibroblast (0.0126) LCN2, CEBPD NFKBIA
MIF-mediated glucocortical regulation (0.0776, NS) PLA2G2A NFKBIA
MIF regulation of innate immunity (0.0195) NOS2, PLA2G2A NFKBIA
HMGB1 signaling (0.0389) VCAM1, PIK3C2G, TNF, TNFRSF11B IL4
Nur 77 signaling in T cells (0.1995, NS) CAMK4 HLA-DRA
this experimental study, such as the limited number of 
animals in each group, and IP injection of a PD solution 
to the rats versus using a catheter in patients, may lead 
to different conclusions.
Conclusion
Our data in this study demonstrates the superiority of 
replacing glucose with HPG on the preservation of PM 
structure and function after daily exposure for 3 months 
in this experimental model of chronic PD. This study 
also conclusively links the deleterious effects of glucose 
to the alterations of inflammatory gene pathways in the 
PM, and it appears HPG may be effective in mitigating 
some of these problems. Taken together with our series 
of acute experiments with HPG-based PD solutions [18, 
19], our present study clearly suggests that HPG is a 
promising novel osmotic agent for use in PD. Currently 
we are investigating the metabolic and pharmacokinetic 
Page 15 of 17Du et al. J Transl Med  (2016) 14:338 
Table 7 The inflammatory signaling pathways and  related gene transcripts affected by  daily injection of  HPG solution 
compared to Control
The affected signaling pathways were ranked from the most (top) to the least significant (bottom) based on the p value
DC dendritic cell, NK natural killer, Th T helper, MΦ macrophage, ICOS inducible costimulator, ICOSL inducible costimulatory ligand, TREM1 triggering receptor 
expressed on myeloid cells 1, MIF macrophage migration inhibitory factor, HMGB1 high mobility group box 1, NS not significant, NC no change
Signaling pathways (p value) Up regulated genes Down regulated genes
B cell development (0.0240) – CD80, HLA-DRA, HLA-DQB1
Complement (0.3006, NS) CFD –
Cross talk between DCs and NK cells (0.0759, NS) – CD80, MICB, HLADRA, ACTC1
Granulocyte adhesion and diapedesis (0.0014) CLDN5, CXCR2, ITGA2, CXCL14, CCL21, CCL11, CXCL6 CXCL10, IL1RAPL1
Agranulocyte adhesion and diapedesis (0.0071) CLDN5, CXCR2, ITGA2, CXCL14, CCL21, CCL11, CXCL6 CXCL10, ACTC1
ICOS/ICOSL signaling in Th cells (0.0063) CD80, GRAP2, HLA-DRA, PIK3C2G, ICOSLG/
LOC102723996
CD80, GRAP2, HLA-DRA, HLA-DQB1
Antigen presentation pathway (0.4875, NS) – HLA-DRA
Nur 77 signaling in T cells (0.0891, NS) – CD80, HLA-DRA, HLA-DQB1
Acute phase response signaling (0.0813, NS) PIK3R3, VWF, KRAS, CRABP1 –
CD28 signaling in Th cells (0.0302) PIK3R3, PIK3C2G CD80, GRAP2, HLA-DRA, HLA-DQB1
IL-17 signaling in fibroblast (0.4677, NS) – CEBPD
Role of hypercytokinemia/hyperchemokinemia in the 
pathogenesis (0.5395, NS)
– CXCL10
IL-10 signaling (NC) – –
Differential regulation of cytokine production in MΦ 
and Th cells (NC)
– –
Inhibition of matrix metalloproteinase (NC) – –
TREM1 signaling (NC) – –
IL-6 signaling (0.1923, NS) PIK3R3, PIK3C2G, KRAS IL1RAPL1
Toll-like receptor signaling (NC) – –
MIF-mediated glucocortical regulation (0.1169, NS) PLA2G5, PLA2G2A –
MIF regulation of innate immunity (0.1660, NS) PLA2G5, PLA2G2A –
HMGB1 signaling (0.4246, NS) PIK3R3, PIK3C2G, KRAS –
Table 8 Triacylglycerol metabolism-related pathways activated by daily injection of HPG solution as compared to Sham 
control
Pathways (p value) Symbol Entrez gene name Fold upregulation
Triacylglycerol degradation (0.0158) FAAH Fatty acid amide hydrolase 2.058
LIPE Lipase, hormone-sensitive 2.014
LPL Lipoprotein lipase 4.845
PNPLA3 Patatin like phospholipase domain containing 3 2.602
CDP diacylglycerol biosynthesis I (0.0316) AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 3.65
CDS1 CDP-diacylglycerol synthase 1 2.755
GPAT3 Glycerol-3-phosphate acyltransferase 3 2.103
Phosphotidylglycerol biosynthesis II (non plastidic) (0.0398) AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 3.65
CDS1 CDP-diacylglycerol synthase 1 2.755
GPAT3 Glycerol-3-phosphate acyltransferase 3 2.103
Triacyglycerol biosynthesis (0.0398) AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 3.65
DGAT2 Diacylglycerol O-acyltransferase 2 3.914
GPAT3 Glycerol-3-phosphate acyltransferase 3 2.103
LPIN2 Lipin 2 2.193
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pathways of HPG in order to ensure that our novel solu-
tion is safe for long-term use in patients with compro-
mised renal function.
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